Drug Trial Radar · NCT07038356
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
536
Planned (sponsor's estimate)
Start
Dec 8, 2025
Primary completion
Apr 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Christian SchulzeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test the hypothesis that the continuation of empagliflozin during decongestive therapy in the setting of acute decompensated and hospitalized heart failure patients is not inferior compared to therapy cessation during the acute heart failure hospitalization. Randomized treatment (plus standard medical care) in patients with acute decompensated heart failure is one (1) tablet daily of empagliflozin 10 mg or matching placebo during the in-hospital stay (up to a maximum of 30 days), followed by treatment with empagliflozin 10 mg daily after discharge (but no later than day 31) until day 90. The primary outcome measure is the combined hierarchical endpoint of all-cause mortality, heart failure hospitalization and worsening renal function at 90 days after admission. Secondary outcome measures are the effects on urine output, diuretic efficiency, quality-of-life and the need for further administration of diuretics. Participants will * Take one tablet of study medication once daily (day 1 to day 90) * Restrict fluid intake to 1.5 liters of fluid per day and record the daily fluid intake for the study from day 1 to day 6 in the patient diary * Measure the urine output (day 1 to day 6) * Fill in Questionnaires (EQ-5D-3L (3-level version of the EuroQol five dimensional descriptive system), KCCQ-12 (Kansas City Cardiomyopathy Questionnaire comprising 12 items)) on day 0 (Baseline), at hospital discharge, and on day 30
Conditions
- Acute Decompensated Heart Failure (ADHF)
Interventions
Empagliflozin 10 MG Oral Tablet [Jardiance]Drug
Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90
PlaceboDrug
Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90
Primary outcomes
What the sponsor says the trial is designed to measure.
- Four-step hierarchical composite primary endpoint; win ratio based on the following parameters (day 90): time to all-cause death, number of heart failure events per patient, time to first heart failure event, eGFR decrease from baseline to day 90Time frame: day 90
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Kerckhoff-Klinik GmbH
Bad Nauheim, Germany · Recruiting
Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin
Berlin, Germany · Recruiting
Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik II, Herzzentrum
Bonn, Germany · Recruiting
Herzzentrum Dresden GmbH Universitaetsklinik
Dresden, Germany · Recruiting
Universitaetsmedizin Goettingen
Göttingen, Germany · Recruiting
Universitätsklinikum Halle (Saale), Klinik für Innere Medizin III
Halle, Germany · Recruiting
Universitaetsklinikum Leipzig AöR
Leipzig, Germany · Recruiting
Herzzentrum Leipzig GmbH
Leipzig, Germany · Recruiting
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Mainz, Germany · Recruiting
LMU Klinikum Muenchen AöR
München, Germany · Recruiting
Rostock University Medical Center
Rostock, Germany · Recruiting
Jena University Hospital
Jena, Thuringia, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.